facebook

The
direct path
to your
donation

     

Alliance

C4R is partner of Network: “Research on Rare Diseases and Personalized Medicine”

We are very proud to be part of the newly established thematic network on “Rare diseases and personalised medicine“ which will start to operate on the 1st of April 2015 at the Dr. von Hauner Children’s Hospital and which will be funded by the German Academic Exchange Service (DAAD). The goal of the network is to introduce new approaches to, and set new standards for, the education and training of physicians and researchers through an international dialogue.

 

Background

Konservierung in flüssigem StickstoffThe strategic objective of this project is, on the one hand, to shed light on the fundamental genetic facts and the pathophysiology of rare diseases of the immune system and to develop new treatment options, and, on the other hand, to induce „new ways of thinking“ in medicine with the help of international expert partners. By promoting mobility and junior researchers the goal is to help patients with rare diseases to step out of their shadowy existence as „the orphans of medicine“ and become a vanguard for a new era of individualised medicine.

 

Goals

The aim is to develop new concepts for diagnosing rare diseases as well as individualised treatments using genetic diseases of the immune system as examples – with a firm focus on the education and training of future physicians and researchers in the context of the thematic network „rare diseases and personalised medicine“. Specific goals are:

  • To intensify mutual research activities in the field of rare immunological diseases- „From discovery to cure“
  • To support a moleculargenomic view of medicine by academic training of „physician-scientists“
  • Bilateral use- a reinforcement of the centre of knowledge that is Germany and promotion of excellent medical care through educating physicians in third world countries
  • To support young researchers in order to ensure long-term international alliances
  • Promotion of mobility
  • To increase public awareness of patients with rare diseases
  • To implement specific training in the field of rare diseases and personalised treatments

 

Action Plan

  1. BlutprobenSupport of PhD candidates’ research stays
  2. Support of students’ and PIs’ short-term stays
  3. Establishment of a biannual summer school and a yearly workshop relating to the topic „rare diseases and personalised medicine“
  4. Implementation of guest lectures with renowned researchers at our partner institutions
  5. Increasing awareness towards rare diseases amongst medical staff, academics and researchers, and the general public.

 

Network

Network map

  • Boston Children’s Hospital, Harvard Medical School, Boston: Scott B. Snapper MD PhD, Director, Inflammatory Bowel Disease Center
  • Hospital for Sick Children, SickKids IBD Centre, University of Toronto: Aleixo Muise MD, PhD, FRCPC, Co-Director SickKids IBD Centre, Division of Gastroenterology
  • Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna: Professor Dr. Josef Penninger, Scientific Director
  • Sheba Academic Medical Center Hospital, Tel Aviv: Dr. Raz Somech, Director Department of General Pediatrics
  • Erciyes University, Faculty of Medicine, Kayseri: Professor Ekrem Ünal, Department of Pediatrics
  • St. Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan: Dr. Roya Sherkat, Director Acquired Immunodeficiency Research Center Isfahan University of Medical Sciences
  • Faculty of Medicine, Chulalongkorn University, Bangkok: Dr. Kanya Suphapeetiporn, Head of Medical Genetics and Metabolism Unit, Department of Pediatrics
  • Helmholtz Zentrum München für Gesundheit und Umwelt
    • Institut für Bioinformatik und Systembiologie (IBIS), Prof. Dr. Hans-Werner Mewes
    • Institut für Computational Biology (ICB), Prof. Dr. Fabian J. Theis
    • Institut für Entwicklungsgenetik (IDG), Prof. Dr. Wolfgang Wurst
    • Institut für Molekulare Immunologie (IMI), Arbeitsgruppe Heissmeyer, Dr. Vigo Heissmeyer
    • Institut für Molekulare Toxikologie and Pharmakologie (TOXI), Assay Development und Screening, Dr. Kamyar Hadian
  • Care-for-Rare Foundation

Dr. Albrecht Matthaei

Tel: + 49 89 4400-57982
Fax: +49 89 4400-57702